WAVE Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its position in WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 38.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 150,513 shares of the company's stock after purchasing an additional 41,429 shares during the period. New York State Common Retirement Fund owned 0.10% of WAVE Life Sciences worth $1,216,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of WVE. GF Fund Management CO. LTD. bought a new stake in shares of WAVE Life Sciences during the 4th quarter valued at about $40,000. Quarry LP bought a new stake in shares of WAVE Life Sciences during the 4th quarter valued at about $62,000. Summit Investment Advisors Inc. boosted its position in shares of WAVE Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock valued at $119,000 after purchasing an additional 2,308 shares in the last quarter. Westwood Wealth Management bought a new stake in shares of WAVE Life Sciences during the 4th quarter valued at about $124,000. Finally, Ameriprise Financial Inc. bought a new stake in shares of WAVE Life Sciences during the 4th quarter valued at about $129,000. Institutional investors and hedge funds own 89.73% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on WAVE Life Sciences in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price objective for the company. Raymond James Financial assumed coverage on WAVE Life Sciences in a research note on Wednesday, June 11th. They issued an "outperform" rating and a $14.00 price objective for the company. Citigroup began coverage on WAVE Life Sciences in a research note on Wednesday, July 16th. They issued a "buy" rating and a $16.00 price objective for the company. Wall Street Zen downgraded WAVE Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Wedbush reaffirmed an "outperform" rating and set a $18.00 price target on shares of WAVE Life Sciences in a research report on Monday, June 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat, WAVE Life Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $20.15.

Insider Buying and Selling at WAVE Life Sciences

In other WAVE Life Sciences news, Director Gregory L. Verdine sold 30,000 shares of the stock in a transaction on Friday, June 13th. The stock was sold at an average price of $6.95, for a total transaction of $208,500.00. Following the sale, the director directly owned 282,517 shares in the company, valued at approximately $1,963,493.15. This trade represents a 9.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 23.98% of the stock is owned by insiders.

WAVE Life Sciences Price Performance

WVE stock traded up $0.01 during mid-day trading on Friday, hitting $8.40. 1,397,484 shares of the stock were exchanged, compared to its average volume of 1,596,268. The business has a fifty day moving average price of $6.97 and a 200 day moving average price of $8.47. WAVE Life Sciences Ltd. has a 12 month low of $5.04 and a 12 month high of $16.74. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -10.00 and a beta of -1.01.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). The business had revenue of $9.18 million during the quarter, compared to analyst estimates of $11.65 million. During the same period last year, the firm earned ($0.24) earnings per share. As a group, equities analysts forecast that WAVE Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

WAVE Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.